Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries

Conclusion Uptake of newer b/tsDMARDs occurred mainly in biologic-experienced patients. Regardless of mode of action, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved LDA. Superior outcomes for adalimumab indicate that the positioning of newer b/tsDMARDs in the PsA treatment algorithm remains to be established.

http://ard.bmj.com/cgi/content/short/82/6/820?rss=1

Source: Annals of the Rheumatic Diseases - May 11, 2023 Category: Rheumatology Authors: Glintborg, B., Di Giuseppe, D., Wallman, J. K., Nordström, D. C., Gudbjornsson, B., Hetland, M. L., Askling, J., Grondal, G., Sokka, T., Provan, S. A., Michelsen, B., Kristianslund, E. K., Dreyer, L., Love, T. J., Lindström, U. Tags: Editor's choice, ARD Lay summaries, ARD, Psoriatic arthritis Source Type: research